A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...
A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...
Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...
Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ...
A research team has successfully engineered a japonica rice variety using CRISPR/Cas9 to simultaneously optimize plant ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Next-Generation Biopharmaceuticals Transforming the Global Therapeutic LandscapeThe Global Bio Pharmaceuticals Market is ...
Ultimately, the collaboration is focused on speeding up progress toward a safer and more resilient food system. As Corbion's ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that makes a longer halt more likely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback